Epigallocatechin gallate and Parkinson Disease

Background: Epigallocatechin gallate (EGCG), a major green tea polyphenol, has attracted interest as a potential neuroprotective agent for Parkinson disease (PD). This review examines its biological rationale, experimental effects, clinical evidence, and safety limitations in the context of dopaminergic degeneration, oxidative stress, neuroinflammation, and abnormal protein aggregation.

Methods: A narrative synthesis evaluates biochemical assays, cellular neurotoxicity models, animal studies, epidemiological observations, and available human trials. Particular attention is given to antioxidant activity, iron chelation, α-synuclein aggregation, intracellular signaling, and the distinction between preclinical neuroprotection and demonstrated clinical benefit.

Results: Experimental findings suggest that EGCG reduces reactive oxygen species, lipid peroxidation, inflammatory mediators, and apoptotic signaling while modulating PKC, MAPK, PI3K/Akt, and Nrf2 pathways. It can inhibit α-synuclein fibrillogenesis and remodel aggregates into less toxic species. MPTP and rotenone models show protection of dopaminergic neurons and improved motor or biochemical outcomes. However, human evidence remains limited. A randomized trial involving 410 untreated patients tested green tea polyphenols rather than isolated EGCG; improvements in Parkinson’s rating scores at six months were not sustained between groups at twelve months, indicating possible symptomatic effects without established disease modification. Poor oral absorption, dose-dependent pro-oxidant activity, and hepatotoxicity complicate translation.

Conclusions: EGCG offers mechanistically plausible neuroprotection, but experimental promise does not establish efficacy for preventing or treating PD. Well-designed controlled trials are needed to clarify clinically meaningful benefits, appropriate exposure, and safety before convincing clinical evidence supports therapeutic use.